BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25876778)

  • 21. New insights into the pathogenesis of chronic lymphocytic leukemia.
    Klein U; Dalla-Favera R
    Semin Cancer Biol; 2010 Dec; 20(6):377-83. PubMed ID: 21029776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation of a targeted DNA microarray for the clinical evaluation of recurrent abnormalities in chronic lymphocytic leukemia.
    Patel A; Kang SH; Lennon PA; Li YF; Rao PN; Abruzzo L; Shaw C; Chinault AC; Cheung SW
    Am J Hematol; 2008 Jul; 83(7):540-6. PubMed ID: 18161787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course.
    Stilgenbauer S; Bullinger L; Lichter P; Döhner H;
    Leukemia; 2002 Jun; 16(6):993-1007. PubMed ID: 12040431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic lymphocytic leukaemia--the role of the microenvironment pathogenesis and therapy.
    Ramsay AD; Rodriguez-Justo M
    Br J Haematol; 2013 Jul; 162(1):15-24. PubMed ID: 23617880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concepts of Chronic Lymphocytic Leukemia Pathogenesis: DNA Damage Response and Tumor Microenvironment.
    Frenzel LP; Reinhardt HC; Pallasch CP
    Oncol Res Treat; 2016; 39(1-2):9-16. PubMed ID: 26889681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How the microenvironment wires the natural history of chronic lymphocytic leukemia.
    Caligaris-Cappio F; Bertilaccio MT; Scielzo C
    Semin Cancer Biol; 2014 Feb; 24():43-8. PubMed ID: 23831274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies.
    Burger JA; Gribben JG
    Semin Cancer Biol; 2014 Feb; 24():71-81. PubMed ID: 24018164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of CD38 Expression in Diagnosis and Pathogenesis of Chronic Lymphocytic Leukemia and Its Potential as Therapeutic Target.
    Burgler S
    Crit Rev Immunol; 2015; 35(5):417-32. PubMed ID: 26853852
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies.
    Kikushige Y
    J Clin Exp Hematop; 2020 Dec; 60(4):146-158. PubMed ID: 33148933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clonal evolution in chronic lymphocytic leukemia: impact of subclonality on disease progression.
    Sutton LA; Rosenquist R
    Expert Rev Hematol; 2015 Feb; 8(1):71-8. PubMed ID: 25345442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adhesion of ZAP-70+ chronic lymphocytic leukemia cells to stromal cells is enhanced by cytokines and blocked by inhibitors of the PI3-kinase pathway.
    Lafarge ST; Johnston JB; Gibson SB; Marshall AJ
    Leuk Res; 2014 Jan; 38(1):109-15. PubMed ID: 23981382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic lymphocytic leukemia: Time to go past genomics?
    Roos-Weil D; Nguyen-Khac F; Bernard OA
    Am J Hematol; 2016 May; 91(5):518-28. PubMed ID: 26800490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes.
    Kienle DL; Korz C; Hosch B; Benner A; Mertens D; Habermann A; Kröber A; Jäger U; Lichter P; Döhner H; Stilgenbauer S
    J Clin Oncol; 2005 Jun; 23(16):3780-92. PubMed ID: 15867199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia.
    Seiffert M; Dietrich S; Jethwa A; Glimm H; Lichter P; Zenz T
    Leuk Lymphoma; 2012 Jun; 53(6):1023-31. PubMed ID: 22023519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Next-generation sequencing in chronic lymphocytic leukemia.
    Villamor N; López-Guillermo A; López-Otín C; Campo E
    Semin Hematol; 2013 Oct; 50(4):286-95. PubMed ID: 24246696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LCK is an important mediator of B-cell receptor signaling in chronic lymphocytic leukemia cells.
    Talab F; Allen JC; Thompson V; Lin K; Slupsky JR
    Mol Cancer Res; 2013 May; 11(5):541-54. PubMed ID: 23505068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting the tumor promoting effects of adenosine in chronic lymphocytic leukemia.
    Cai Y; Feng L; Wang X
    Crit Rev Oncol Hematol; 2018 Jun; 126():24-31. PubMed ID: 29759563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies.
    Damm F; Nguyen-Khac F; Fontenay M; Bernard OA
    Leukemia; 2012 Sep; 26(9):2027-31. PubMed ID: 22484420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B-cell receptor structure, function, and patients' prognosis.
    Del Giudice I; Chiaretti S; Santangelo S; Tavolaro S; Peragine N; Marinelli M; Ilari C; Raponi S; Messina M; Nanni M; Mauro FR; Piciocchi A; Bontempi K; Rossi D; Gaidano G; Guarini A; Foà R
    Am J Hematol; 2014 Jan; 89(1):74-82. PubMed ID: 24030933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic lymphocytic leukemia cells are activated and proliferate in response to specific T helper cells.
    Os A; Bürgler S; Ribes AP; Funderud A; Wang D; Thompson KM; Tjønnfjord GE; Bogen B; Munthe LA
    Cell Rep; 2013 Aug; 4(3):566-77. PubMed ID: 23933259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.